1. HBW Insight
  2. >>Wellness
  3. >>Policy & Regulation
  4. >>Recalls

First Recalls, Now Investors' Concerns Over Ranitidine Litigation Take Pharmas For Wild Ride

 
• By Kevin Grogan and Hannah Daniel

Host of complaints in US courts, seeking damages or alleging ranitidine caused various cancers, followed FDA’s 2020 findings of NDMA levels exceeding allowable limits in some samples provoked  Litigation is starting to come to trial, the first set for 22 August in Illinois and a bellwether case due to begin in California in February 2023.

• Source: Shutterstock

Pharma industry investors have become nervous about litigation over OTC and Rx ranitidine-containing drugs, with several firms’ share price recently tumbling as the start of court trials approaches.

GlaxoSmithKline plc developed the most well-known Rx ranitidine brand indicated for heartburn, Zantac, and following its launch in the early 1980s the product became the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Recalls

More from Policy & Regulation